PD33-05 THE NATURAL HISTORY OF IDIOPATHIC OVERACTIVE BLADDER AFTER SACRAL NEUROMODULATION

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD33-05 THE NATURAL HISTORY OF IDIOPATHIC OVERACTIVE BLADDER AFTER SACRAL NEUROMODULATION Yu Zheng, Stephanie Daignault-Newton, Paholo Barboglio Romo, Priyanka Gupta, Anne P Cameron, John T Stoffel, Lauren Wallner, Aruna Sarma, J. Quentin Clemens, and Giulia Lane Yu ZhengYu Zheng More articles by this author , Stephanie Daignault-NewtonStephanie Daignault-Newton More articles by this author , Paholo Barboglio RomoPaholo Barboglio Romo More articles by this author , Priyanka GuptaPriyanka Gupta More articles by this author , Anne P CameronAnne P Cameron More articles by this author , John T StoffelJohn T Stoffel More articles by this author , Lauren WallnerLauren Wallner More articles by this author , Aruna SarmaAruna Sarma More articles by this author , J. Quentin ClemensJ. Quentin Clemens More articles by this author , and Giulia LaneGiulia Lane More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003326.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We aim to evaluate rates of anticholinergic, beta-3 agonist or onabotulinum toxin-A (BTX-A) use among women who had sacral neuromodulation (SNM) placed for idiopathic overactive bladder (iOAB). METHODS: Electronic health records were used to identify adult women who underwent stage II SNM for diagnosis of iOAB from 2012 to 2021. We excluded patients with prior BTX-A use (N=21) and those who did not follow-up after SNM placement (N=4). We queried for rates of anticholinergic, beta-3 agonist or onabotulinum toxin-A use following SNM placement (termed, salvage therapy). Kaplan-Meier methods were used to estimate event rates at 4 years and median time-to-salvage. Censoring occurred at the latest date among the following events: urology visit, OAB med prescription, botox intervention, or SNM removal. RESULTS: Among 296 patients who tested SNM, 254 (86%) patients underwent stage II SNM placement and were included in the study, median follow-up time was 33.7 months. Of these, 83% were female with median age of 60 years (IQR 49-71). Among those who underwent SNM stage II, explantation rate was 25% (95% CI: 19 -34%) at 4 years with 43 patients having a recorded explantation. Of 254 patients, 91 patients had new prescriptions for anticholinergics (N=59) or beta-3 agonist (N=60) with 35.8% (95% CI: 36 – 72%) of patients with a prescription within 4 years. Of 254 patients, 24 underwent BTX-A with a proportion of 9.5% (95% CI: 7 – 19%) at 4 years after initial SNM II. Time to salvage treatment occurred at a median of 47 months (95% CI: 37 – 69mo) after SNM (Figure 1). CONCLUSIONS: In our cohort, nearly a third of patients had new prescriptions for medical management for iOAB and 9.5% started BTX-A at 4 years following initial SNM II placement. Source of Funding: K12 -DK111011-06 UroEPI Career Development Program at the University of Michigan Department of Urology © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e915 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Yu Zheng More articles by this author Stephanie Daignault-Newton More articles by this author Paholo Barboglio Romo More articles by this author Priyanka Gupta More articles by this author Anne P Cameron More articles by this author John T Stoffel More articles by this author Lauren Wallner More articles by this author Aruna Sarma More articles by this author J. Quentin Clemens More articles by this author Giulia Lane More articles by this author Expand All Advertisement PDF downloadLoading ...